For many pharmaceutical companies, receiving a positive recommendation from NICE represents a significant milestone. After years of clinical development, regulatory review and health technology assessment, it is often viewed as the point at which patients will finally gain access to an innovative medicine.
Unfortunately, the reality across the NHS is often very different.
The 90-Day Rule – But Not Always the Reality
In England, NHS organisations are expected to make NICE-recommended medicines routinely available within 90 days of publication of Technology Appraisal guidance. The intention is clear: patients should benefit from clinically and cost-effective treatments without unnecessary delay.
However, many companies continue to experience considerable variation between Integrated Care Boards (ICBs). While some systems mobilise quickly, others take significantly longer before clinicians can routinely prescribe a newly recommended medicine.
For manufacturers, this creates an increasingly familiar frustration. National approval does not automatically translate into local adoption.
Why Are Delays Increasing?
The NHS has undergone substantial organisational change over the past two years.
ICBs have been asked to deliver significant efficiency savings while simultaneously reducing management and administrative costs. Medicines optimisation teams, formulary pharmacists and commissioning staff are managing larger portfolios with fewer resources, often while supporting wider organisational transformation.
The consequence is that local formulary reviews, governance meetings and implementation planning can take longer than previously.
These delays rarely reflect a lack of clinical support for the medicine itself. More commonly, they are the result of competing priorities and constrained capacity.
Priority Matters
Not every new medicine receives the same level of organisational focus.
Products addressing nationally prioritised conditions or delivering immediate financial or operational benefits are often progressed more rapidly. In contrast, medicines for smaller patient populations, specialist services or conditions perceived as lower strategic priorities may wait considerably longer for local review.
Even where there is a legal funding requirement following NICE guidance, practical implementation still requires local action:
- Formulary updates
- Clinical pathway amendments
- Medicines optimisation review
- Prescriber education
- Governance approval
- Communication across provider organisations
If these activities are delayed, patient access is delayed.
Local Engagement Has Never Been More Important
In today’s NHS, companies cannot assume that publication of NICE guidance alone will drive implementation.
Successful launches increasingly depend upon proactive engagement with local stakeholders before and immediately after NICE publication. This includes ensuring that:
Medicines optimisation teams understand the clinical value proposition
- Local budget holders have planned for financial impact
- Clinical champions are prepared to support implementation
- Care pathways are ready to incorporate the new treatment
- Local decision-makers have the information they need to prioritise review
The earlier these conversations begin, the greater the opportunity to minimise avoidable delays.
Understanding Local Variation
Every ICB is different.
Some maintain well-established formulary processes with predictable timelines. Others are still adapting following organisational restructuring and workforce changes.
Understanding where each system sits, its governance processes, decision-making cadence, key stakeholders and competing priorities, allows companies to target support where it will have the greatest impact.
A national strategy remains essential, but increasingly it must be complemented by tailored local market access activity.
Looking Ahead
The NHS continues to evolve, and pressure on local commissioning and medicines optimisation teams is unlikely to reduce in the near future.
For pharmaceutical companies, this means launch excellence is becoming less about achieving NICE approval alone and more about ensuring that local systems are ready to implement it.
Positive NICE guidance opens the door, but it does not guarantee that every patient will have timely access.
The organisations that achieve the fastest and broadest uptake will be those that combine strong national evidence with informed, coordinated and proactive local engagement, helping NHS stakeholders navigate competing priorities and ensuring that innovative medicines reach the patients who stand to benefit most.
How prepared is your launch for local implementation?
As NHS structures continue to evolve, understanding local decision-making has never been more important. Organisations that invest in early engagement with ICBs, medicines optimisation teams and provider organisations are better positioned to reduce delays and accelerate patient access following NICE approval.